Chengdu Olymvax Biopharmaceuticals (SH:688319) Guo Ji Jin Rong Bao·2025-11-29 14:33Core Viewpoint - Company Olin Bio (688319.SH) has submitted an application for a mainboard listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, aiming to leverage its strong market position in the vaccine sector [1][2] Group 1: Company Overview - Olin Bio is a biopharmaceutical company focusing on unmet medical needs in "super bacteria vaccines" and "adult vaccines" [2] - The company has three commercialized products: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine [2] - Olin Bio's Tetanus Toxoid Vaccine holds over 80% market share in China as of 2024 [2] Group 2: Financial Performance - Revenue for Olin Bio during the reporting period (2022-2025) was 5.47 billion, 4.94 billion, 5.86 billion, and 3.05 billion respectively, showing significant fluctuations [4] - The annual profit and total comprehensive income were 26.58 million, 11.44 million, 15.72 million, and 13.23 million respectively, with 2023 and 2024 figures lower than 2022 [4] - Gross profit margins were consistently high at 92.3%, 93.1%, 94%, and 92.3% over the same period [4] Group 3: Revenue Sources - A significant portion of Olin Bio's revenue comes from the Tetanus Toxoid Vaccine, contributing approximately 4.377 billion, 4.63 billion, 5.358 billion, and 2.683 billion during the reporting period, accounting for around 80% to 93.7% of total revenue [5]